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Received 23 June 2007; received in revised form 18 September 2007; accepted 27 September 2007; Available online 8 January 2008AbstractBackground: Malignant pleural mesothelioma (MPM) is a highly aggressive tumour with poor prognosis and limited response to therapy. MPM is
characterised by complex chromosomal aberrations, including chromosome 10 losses. The tumour suppressor gene phosphatase and tensin
homologue deleted from chromosome 10 (PTEN) located on chromosome 10q23 plays an important role in different cancer, but its relevance for
MPM is unclear. Patients and methods: In the present tissue microarray-based study, 341 MPM were studied for PTEN expression by
immunohistochemistry using a monoclonal mouse PTEN antibody. Expression levels were semiquantitatively scored (negative, weak, moderate,
strong). Expression of PTEN was correlated to overall survival. Results: Clinical data from 206 patients were available. One hundred and five
patients were stage T4 and 92 patients presented with regional and mediastinal lymph node metastasis. Loss of PTEN expression was observed in
62% of the cases. The survival time was correlated to PTEN expression in 126 cases with complete follow-up data. Comparing any PTEN expression
versus no expression, median survival time was significantly longer (log rank test p = 0.0001) in patients with PTEN expression (15.5 months; 95%
CI: 3.8; 27.2 vs 9.7 months; 95% CI: 7.9; 11.7). Cox regression analysis revealed an association between PTEN expression and survival ( p = 0.003)
independently from the histological subtype ( p = 0.7). Conclusion: PTEN is an independent prognostic biomarker in mesothelioma patients. The
frequent loss of expression of the tumour suppressor gene PTEN suggests involvement of the PI3K-AKT/protein kinase B (PKB) pathway in MPMs,
which may be relevant for future mesothelioma treatment.
# 2008 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Malignant pleural mesothelioma (MPM) is a fatal disease
with an increasing incidence in the United States andWestern
Europe until approximately 2020 [1]. Without treatment, the
majority of patients will die within 6—18 months [2].
Response to standard chemotherapy is moderate, the
greatest treatment success is currently reached by multi-
modal treatment offering a median survival of 23 months [3].
Patients with an epithelioid subtype are known to experience
a longer survival in comparison to patients with other
subtypes (sarcomatoid, biphasic) [4]. But nevertheless, there
is a strong variability in patient survival and therapy response
that is not explained only by tumour stage and histological§ Presented at the 15th European Conference on General Thoracic Surgery,
Leuven, Belgium, June 3—6, 2007.
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doi:10.1016/j.ejcts.2007.09.045subtype and may be due to biological variability. As a
consequence of asbestos exposure, the major risk factor for
the development of MPM [5], a chronic inflammation process
occurs that leads over a long latency period to tumour
development where different growth factors, signalling
molecules, oncogenes and tumour suppressor genes have
been hypothesised to be involved [6]. Therapeutic
approaches targeting these signal transduction cascades
may control MPM tumour cell growth and proliferation.
The tumour suppressor gene phosphatase and tensin
homologue deleted from chromosome 10 (PTEN), also known
as MMAC1 (mutated in multiple advanced cancers) or TEP1
(TGFb-regulated and epithelioid cell-enriched phosphatase),
is located on chromosome 10q23 and encodes protein
regulating various signal transduction pathways and mod-
ulating cell growth processes, cell migration and apoptosis
[7]. Mutations of this gene have been identified in a large
fraction of tumours, including gliomas, endometrial cancers,
breast, thyroid, bladder, ovary, small cell lung cancer and
haematological malignancies [8]. In MPM, chromosome 10Surgery. Published by Elsevier B.V. All rights reserved.
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Table 1
TNM staging according to IMIG [11]






Unknown 58 (28.5%)losses have been detected by comparative genomic hybri-
disation [9], therefore analysis of PTEN expression located on
10q23 might elucidate an interesting factor of mesothelioma
carcinogenesis.
Consequently, the aim of the underlying study was to
screen a large tissue bank consisting of 341 formalin-fixed,
paraffin-embedded MPM biopsy specimens for the expression












Univariate analysis of different prognostic factors on survival: PTEN-score (0 vs






Histology 0.012. Patients and methods
2.1. Patients
All malignant mesotheliomas, diagnosed between 1975
and 2004, were retrieved from the archives of the Zurich
Pneumoconiosis Research Group, Switzerland (Director: M.
Rueegger). The total of 341 cases comprised 112 epithelioid,
183 biphasic and 46 sarcomatoid types. The tissue specimens
were mainly derived from post-mortem examination (77%
autopsy, 23% biopsy) and had uniformly been formalin-fixed
and paraffin-embedded. They had all been originally
examined and classified for the histological subtype by one
experienced lung pathologist (P.V.) and were reviewed (M.H.)
to identify suitable areas for tissue microarray construction.
2.2. Tissue microarray construction
The construction of a set of three tissue microarrays was
accomplished with a custom-made, semiautomatic tissue
arrayer (Beecher Instruments, Sun Prairie, WI, USA) as
described previously [10].
2.3. Immunohistochemistry
PTEN immunohistochemistry was first established on a
multi-tumour-TMA consisting of the most frequent human
tissues and carcinomas. 4.5 mm sections of tissue microarray
blocks were transferred to an adhesive-coated slide system
(Instrumedics, Hackensack, NJ, USA) supporting the cohesion
of 0.6 mm array elements on glass. De-paraffined sections
were automatically stained with BenchMark (Ventana, USA)
using the iView DAB Detection kit (Ventana, USA).
The primary antibody for the expression of PTEN was a
mouse monoclonal antibody (Novocastra, Sweden) diluted
1:200 and incubated for 30 min. PTEN expressing endome-
trioid adenocarcinoma of the uterus was used as a positive
control, because PTEN is frequently inactivated by mutation
and deletion in endometrioid carcinomas.
2.4. Data assessment and statistical analysis
The sections were semiquantitatively assessed for the
cytoplasmatic PTEN expression by one observer (A.S.).
Intensity of staining was scored semiquantitatively 0
(negative), 1 (weak), 2 (moderate) and 3 (strong). Clinical
data of these patients were retrospectively assessed from
medical archives of the different hospitals and the local
cancer registries. Statistical analysis was performed using
Kaplan—Meier curves for correlation of survival time withexpression of PTEN. For correlation between ordinal vari-
ables (including dichotomised variables: epithelioid vs non-
epithelioid correlated to PTEN expression score), we used the
gamma-coefficient. The joint influence of both predictors on
survival was assessed by Cox regression analysis.3. Results
Clinical data were assessed for a total of 206 patients (94%
male) with a median age of 63 years (39; 97). Exposure to
asbestos was known in 97 cases (47.1%). Disease was located
in 52% of the patients on the right side. The histological
subtype was epithelioid in 63 (31%) patients, in 109 (52%) a
biphasic and in 34 (17%) patients a sarcomatoid. As tumour
stage was not documented in every case, a retrospective
staging was performed based on pathology reports’ descrip-
tion according to the IMIG staging system [11]. Complete
tumour stage is summarised in Table 1. Treatment was in 61
cases (30%) surgical and comprised 27 extrapleural pneumo-
nectomies, 16 pleurectomies and 18 palliative procedures as
talc pleurodesis or tumour debulking. A total of eight patients
only received chemotherapy that was in all cases platinol-
based in combination with gemcitabine, mitomycin or others
(Table 2).
Survival data were assessed for 129 patients with amedian
overall survival of 11.7 months (95% CI 9.7; 13.7).
PTEN expression was lost in 62% of the cases (score 0)
whereas 14% presented weak (score 1), 10% moderate (score
2) and 14% strong expression of PTEN (Fig. 1). All PTEN
expression levels were observed in every histological subtype
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Fig. 1. PTEN expression score 0 (negative), 1 (weak), 2 (moderate) and 3
(strong expression).
Fig. 2. Malignant mesothelioma tissue microarray: immunohistochemistry
with PTEN antibody. No versus strong expression of an epithelioid malignant
mesothelioma (upper panel) and no versus strong expression of a sarcomatoid
malignant mesothelioma (lower panel).
Fig. 3. Survival according to PTEN expression. PTEN negativity (black) versus
PTEN expression (weak—moderate—strong expression, grey).
Fig. 4. Survival according to PTEN expression. PTEN negativity (0: black)
versus weak (1: light-grey), moderate (2: dotted) and strong (3: dark-grey)
PTEN expression.(Fig. 2) and statistically PTEN expression did not correlate
with the histological subtype (gamma-coefficient 0.01,
p = 0.9).
Survival was strongly correlated to PTEN expression
comparing no (score 0: median survival 9.7 months, 95% CI
7.9; 11.7) versus weak—moderate—strong expression (score
1—3: median survival 15.5, 95% CI: 3.8; 27.2) (log rank
p = 0.0001) (Fig. 3). Even the comparison of the different
PTEN expression scores (0 vs 1 vs 2 vs 3) showed a significant
impact on overall survival ( p = 0.0003) (Fig. 4). Moreover, the
histological subtype significantly influenced the overall
survival with the best survival data of patients with an
epithelioid or biphasic subtype (median survival 12.7months,
95% CI 8.4; 17 and median survival of 13.1 months, 95% CI
10.9; 15.3, respectively) and a shorter survival of patients
with a sarcomatoid subtype (median survival 6.5 months, 95%
CI 4.9; 8.2) (log rank p = 0.01). Patients undergoing surgery
had a significant better median survival (14.2, 95% CI 9.45;18.89) than patients without surgery (9.6, 95% CI 6.9; 12.4)
( p = 0.0015) and younger patients (62) also had a significant
better prognosis with a median survival of 12.6 months (95%
CI 8.4; 16.9) in comparison to older patients (median survival
of 10.9, 95% CI 6.2; 15.6).
Cox regression analysis revealed a prognostic influence of
PTEN expression (no vs weak—strong expression) on survival
( p = 0.003) independently from the histological subtype
(epithelioid vs non-epithelioid) ( p = 0.7), age ( p = 0.3) or
surgery (0.09).4. Discussion
In this large TMA-based study, we were able to
demonstrate that loss of PTEN expression occurs in 62% in
MPM. Loss of PTEN expression was strongly correlated with
shorter survival, independently from the histological sub-
type. Different biomarkers for the prediction of patient
prognosis have been suggested for MPM patients. However,
previous immunohistochemical biomarker screening of MPM
was based on relatively small numbers of tissue samples [12—
15]. In contrast, our study used a TMA with MPM tissue of 341
patients. Clinical data, including staging were available from
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from 129 patients allowing retrospective survival analysis.
Although data assessment was performed retrospectively and
therefore not as complete as in prospective analysis and
treatment concepts were inconsistent at this time period,
the underlying study represents to our knowledge the largest
immunohistochemical screening of mesothelioma specimens
for the expression of a biomarker with correlation to clinical
data. There is only one other report looking at EGFR
expression in mesothelioma [16]. Numerous investigations
have meanwhile provided strong evidence on the represen-
tativeness of TMA data for biomarker analysis and on the
reproducibility of the biological relevance of several
markers, e.g. the clinical significance of Ki-67 labeling index
in bladder cancer or the prognostic role of steroid hormone
receptor expression and Her2 neu amplification/overexpres-
sion in breast cancer [17].
An association between PTEN negativity by immunohis-
tochemistry and poor prognosis was previously shown for
some other cancer types, such as breast and renal cell
carcinoma [18,19]. PTEN inactivation is probably the most
common [20,21] as well as the most potent lesion of the
oncogenic phosphatidylinositol-kinase (PI3K) signalling path-
way, which has been implicated in nearly all aspects of
tumour biology: cell transformation, growth, proliferation,
migration, protection, apoptosis, genomic instability, angio-
genesis, metastasis and cancer stem cell maintenance
[20,22]. Aberrant PI3K pathway signalling is estimated to
be present in >30% of human cancers [20] and occurs beside
oncogenic alterations by inactivation of PTEN which is the
pathway’s most important regulatory brake. It is a plasma-
membrane lipid phosphatase that antagonises the function of
the PI3K-AKT/protein kinase B (PKB) pathway. One key
protein that is dephosphorylated by wild-type PTEN is the
serine-threonine kinase AKT. Phosphorylated AKT, the active
form of this kinase, promotes cell survival through multiple
pathways, many of which are associated with cell growth and
survival. Levels of phosphorylated AKT have been reported to
be increased in multiple tumours [23]. It was also demon-
strated in mesothelioma that the AKT/mTOR pathway is
frequently activated in both human and murine MPM
specimens and MPM cell lines [24]. Immunohistochemical
analysis revealed elevated levels of phospho-AKT in nearly
two-thirds of human primary MPM. A strong association with
elevated phospho-mTOR positivity in the same tumours
confirmed activation of the AKT pathway [8].
PTEN silencing occurs via loss of heterozygosity (LOH) at
locus 10q23.3 and mutation of the PTEN tumour suppressor
gene in endometrioid and prostate cancer. In MPM, chromo-
some 10 losses have been detected by comparative genomic
hybridisation [9], suggesting PTEN as the target tumour
suppressor gene on 10q in MPM. However, a PTEN loss of
heterozygosity (LOH) was found in only 1 out of 9 cell lines and
protein loss in only 2 out of 26MPMby Altomare et al. [24]. The
discrepancy in the immunohistochemical result can be
explained by using different antibodies (Santa Cruz vs
Novocastra). According to our experience, the antibody by
Novocastra shows the best correlation with LOH of PTEN.
Nevertheless, further studies are necessary to evaluate the
mutation status of this tumour suppressor gene in MPM. Apart
from this study, PTEN expression in primary MPM specimenswasnot yet analysed ina largerextent. Importantly,Mohiuddin
et al. [25] have recently demonstrated in mesothelioma cell
lines transfected with adenoviral vector AdPTEN that
apoptosis via inhibition of AKT phosphorylation occurs.
In summary, our data strongly indicate that PI3K pathway
is involved in MPM carcinogenesis and is an independent
prognostic factor. As novel agents like PI3kinase-inhibitors
and mTOR-inhibitor, which interfere upstream or down-
stream to PTEN, are already under clinical investigation,
there might be a rationale to use these new low-toxicity
pharmaceuticals for MPM.Acknowledgements
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Appendix A. Conference discussion
Dr A. Patterson (St Louis, MO): I would like to congratulate you with this
very elegant presentation and I think it is very interesting. I would like to askyou about the survival of your patients, if there were any patients who were
cured of mesothelioma? Because my impression from the survival cases you
presented was that there were no cures; that all patients even died early from
mesothelioma, but maybe the progression was slower in patients with PTEN
factor.
So I think it is very important to state if this factor is prognostically good
that the patient can be cured or the progression is slower, that is the question.
Dr Opitz: As mentioned, the biopsy specimens date from the beginning of
1975 until 2004. At this era there was no standardised treatment for
malignant pleural mesothelioma and over 70% of the biopsy specimens were
extracted during autopsy. The majority of the patients had no treatment or
palliative approaches, only a few underwent extrapleural pneumonectomy
mainly after 2000. Therefore, these data cannot be correlated with
treatment. We perform now a prospective analysis in order to assess
treatment response after chemotherapy and prognosis of trimodality
therapy.
Dr M. Zielinski (Zakopane, Poland): It was a great presentation. I think
this kind of work is critically important to understand tumour biology not only
for a mesothelioma but also for all malignancy that we deal with. It is great to
have 300 cases of pathologic specimens to review retrospectively but as you
just said the majority of these patients had really no idea what the clinical
staging was. So do you have any sense of what has given you recent practice of
detailed staging and surgical resection in patients who you think have
favourable disease. Do you think that PTEN influence on survival would
actually have an impact in patientswho have favourable tumours and undergo
resection?
Do you think patients with PTEN expression aremuchmore likely to present
with advance disease and patients without PTEN expression are very unlikely
to have, in reality, favourable lesions?
Dr Opitz: PTEN was already assessed in other tumours like renal carcinoma
or breast carcinoma and it was proven that the stage of disease and the
response to therapy correlated to PTEN expression. There are also studies
showing that chemotherapy resistance is also dependent on the loss of PTEN
expression because of Akt-activation. So it would be very interesting to see if
this is also the case for mesothelioma patients.
Dr A. Turna (Istanbul, Turkey): You apparently used a tissue bank, but did
you look at the heterogeneity of the PTEN expression throughout the tissue,
because usually mesothelioma is known to be heterogeneous in terms of
oncogenic protein expression. And a second question is that do you know the
rate of the patients who are first generation Turkish immigrants among your
patients? These patients could be different because of the carcinogenesis
under asbestosis.
Dr Opitz: First to your second question: There was no Turkish immigrant in
this series. It is true that PTEN is known for many tumours to have a loss of
heterozygosity but we just started to look at this. From another study in 18
mesothelioma patients they showed that disarrangement of PTEN seems not to
be frequently involved in mesothelioma.
Dr G. Varela (Salamanca, Spain): I wonder if you should havemeasured the
interobserver variability because scoring this way is rather subjective.
Dr Opitz: Yes! We should do that, it is true.
